Risk factors predicting the survival of pediatric patients with relapsed/refractory non-Hodgkin lymphoma who underwent hematopoietic stem cell transplantation: a retrospective study from the Turkish pediatric bone marrow transplantation registry
Makaleler > Tam Makale · 2017
Yazarlar: Volkan Hazar, Vural Kesik, Gülsün Tezcan Karasu, Gülyüz Öztürk, Alphan Küpesiz, Suar Çakı Kılıç, Erman Ataş, Vedat Uygun, Nurşah Eker, Fatih Erbey, Şebnem Yılmaz Bengoa, Suna Emir, Sema Anak, Haldun Öniz, Hayriye Daloğlu, Serap AKSOYLAR, Ülker Koçak, Musa Karakükçü, Murat Elli, Nilgün Kurucu, Akif Yeşilipek
Leukemia & Lymphoma, Uluslararası, Wos, 2017, cilt 59, ss 85-96
DOI: 10.1080/10428194.2017.1330472
Özet
We examined outcomes of 62 pediatric patients with relapsed or refractory non-Hodgkin lymphoma (rr-NHL) who underwent hematopoietic stem cell transplantation (HSCT). The overall survival (OS) and event-free survival (EFS) rates were 65% and 48%, respectively. Survival rates for patients with chemosensitive disease at the time of HSCT were significantly higher than those of patients with chemoresistant disease (69% vs. 37%, p = .019 for OS; 54% vs. 12%, p < .001 for EFS; respectively). A chemoresistant disease at transplantation was the only factor that predicted a limited OS (hazard ratio = 10.00) and EFS (hazard ratio = 16.39) rates. Intensive chemotherapy followed by HSCT could be an effective strategy for treating children with rr-NHL and may offer improved survival for a significant group of pediatric patients, particularly those with chemosensitive disease at transplantation.